MeiraGTx Limited
MGTX · Nasdaq · United States
Share price · MGTX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when MGTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 13 Nov 2026+4.4%
- 12 Nov 2026-9.2%
- 14 Oct 2026-5.3%
Nothing announced by MGTX that day or the session before.
- 24 Sep 2026-6.0%
- 22 Sep 2026-5.6%
Nothing announced by MGTX that day or the session before.
- 14 Aug 2026+6.7%
- 30 Jun 2026+7.7%
Nothing announced by MGTX that day or the session before.
- 18 Jun 2026+8.7%
Nothing announced by MGTX that day or the session before.
- 16 Apr 2026-15.7%
Nothing announced by MGTX that day or the session before.
- 14 Apr 2026+17.2%
Nothing announced by MGTX that day or the session before.
Share of unusual movement by asset
For each asset, the share of MGTX's own-move activity since 3 Nov 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 7% |
| Sessions with no dated event | — | 93% |
No dated announcements about its assets since 3 Nov 2025.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Glutamic acid decarboxylase (GAD) gene delivered to the subthalamic nucleusGene therapy / editing | Parkinson's Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
October 2029 (1)
What to watch
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $4.8M | $39M | $187M | $51M-$25M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $321M | $58M | $145M | —-$39M operating cash flow | report ↗ |
| 2026-Q1 | $0.3M | $32M | $74M | $46M$18M operating cash flow | report ↗ |
| 2025-Q3 | $0.4M | $33M | $17M | $51M-$12M operating cash flow | report ↗ |
| 2025-Q2 | $3.7M | $33M | $34M | $39M-$44M operating cash flow | report ↗ |
| 2025-Q1 | $1.9M | $33M | $69M | $40M-$37M operating cash flow | report ↗ |
| 2024-Q3 | $11M | $26M | $125M | $39M-$25M operating cash flow | report ↗ |
| 2024-Q2 | $0.3M | $35M | $101M | $49M-$19M operating cash flow | report ↗ |
| 2024-Q1 | $0.7M | $34M | $120M | $20M-$37M operating cash flow | report ↗ |
| 2023-Q3 | $5.1M | $28M | $64M | $44M-$24M operating cash flow | report ↗ |
| 2023-Q2 | $3.5M | $20M | $93M | $30M-$29M operating cash flow | report ↗ |
| 2023-Q1 | $3.3M | $22M | $69M | $30M-$37M operating cash flow | report ↗ |
| 2022-Q3 | — | $17M | $115M | $37M-$21M operating cash flow | report ↗ |
| 2022-Q2 | — | $24M | $72M | $34M-$28M operating cash flow | report ↗ |
| 2022-Q1 | — | $23M | $114M | $31M-$8.3M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $81M | $130M | $68M | $29M-$46M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 11 sales ($5.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | Forbes Alexandria · director, PRESIDENT & CEO | Gift | 24,100 | — | — | Form 4 |
| 2026-11-17 | Forbes Alexandria · director, PRESIDENT & CEO | Open-market sale | 62,000 | $8.45 | $524K | Form 4 |
| 2026-10-20 | Giroux Richard · CFO & COO | Open-market sale | 56,000 | $9.95 | $557K | Form 4 |
| 2026-10-06 | Naylor Stuart · CHIEF SCI OFCR, OPHTHALMOLOGY | Open-market sale | 27,659 | $10.64 | $294K | Form 4 |
| 2026-09-23 | SEBULSKY ALAN · director | Award / grant (derivative) | 100,000 | — | — | Form 4 |
| 2026-08-18 | Forbes Alexandria · director, PRESIDENT & CEO | Open-market sale | 62,000 | $13.86 | $859K | Form 4 |
| 2026-07-21 | Giroux Richard · CFO & COO | Open-market sale | 56,000 | $12.51 | $701K | Form 4 |
| 2026-07-07 | Naylor Stuart · CHIEF SCI OFCR, OPHTHALMOLOGY | Open-market sale | 2,547 | $13.86 | $35K | Form 4 |